Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

742.12
+3.400.46%
Pre-market: 720.99-21.1267-2.85%04:00 EDT
Volume:626.43K
Turnover:466.05M
Market Cap:76.40B
PE:18.35
High:753.68
Open:738.05
Low:734.18
Close:738.72
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.82
T/O Rate:0.63%
Dividend:3.64
Dividend Rate:0.49%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.41
PE(LYR):17.89

Loading ...

Analysts’ Top Healthcare Picks: Regeneron (REGN), Idexx Laboratories (IDXX)

TIPRANKS
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

Barclays Sticks to Its Buy Rating for Regeneron (REGN)

TIPRANKS
·
Oct 02

Regeneron Pharmaceuticals, Inc. : Jefferies Raises Target Price to $930 from $870

THOMSON REUTERS
·
Oct 02

Jefferies Sticks to Their Buy Rating for Regeneron (REGN)

TIPRANKS
·
Oct 02

Regeneron price target raised to $930 from $870 at Jefferies

TIPRANKS
·
Oct 02

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

TIPRANKS
·
Oct 02

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Oct 01

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS
·
Oct 01

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS
·
Oct 01

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire
·
Oct 01

Regeneron Says Phase 2 Courage Trial Shows Trevogrumab Preserves Lean Mass During Semaglutide Weight Loss

Reuters
·
Oct 01

Regeneron Pharmaceuticals, - Lower Doses of Trevogrumab Well Tolerated with 77% Experiencing at Least One Adverse Event

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Plans Phase 2 Trial of Trevogrumab with Glp-1 Therapies in Older Adults

THOMSON REUTERS
·
Oct 01

Phase 2 Courage Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During Glp-1 Receptor Agonist-Induced Weight Loss

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Trevogrumab Prevents 70% of Muscle Loss Associated with Semaglutide Treatment

THOMSON REUTERS
·
Oct 01

Movement Alert|Regeneron Pharmaceuticals Falls 3.08% in Regular Trading, Expanded Sanofi Alliance Fails to Meet Investor Expectations on Deal Terms

Market Focus
·
Oct 01